CD4 and neoplasm: In light of the observations reported above for an increased HLA-II presentation in mo-DCs loaded with HOCl-treated tumor lysates, we decided to specifically investigate the CD4+ T cell responses elicited by the OCDC vaccine in another subset of 18 patients treated under the same protocol.